Over 100 years serving the Lord home and around the world
First Baptist Church
We are a church who's members come from many nations of origin to worship together!


Biogen Idec third one fourth revenues boost 11 percent to $1.

Price of Sales is likely to be around 9 percent to 10 percent of total income. R&D is likely to end up being at the top quality of 22 percent to 24 percent of total income. SG&A is likely to become at the top quality of 20 percent to 21 percent of total revenue. Taxes rate is likely to be around 26 percent to 28 percent of pretax income. GAAP diluted EPS is definitely likely to be above $4.91. Non-GAAP diluted EPS is usually expected to end up being above $5.70. Capital expenditures are anticipated to become in the number of $200 to $220 million. Biogen Idec might incur charges, realize gains or encounter other events in 2011 that might lead to actual results to change from this guidance. Recent Occasions Showcasing world-course R&D On October 26, 2011, Biogen Idec announced positive topline outcomes for CONFIRM, the next of two pivotal Stage III clinical trials made to measure the investigational oral substance BG-12 in people who have relapsing-remitting multiple sclerosis . Continue reading

Collaborative home-based palliative look after heart failure effective in UK By Sarah Man.

Collaborative home-based palliative look after heart failure effective in UK By Sarah Man, medwireNews Reporter A collaborative home-based palliative care assistance for sufferers with advanced congestive heart failing could increase their chances of dying in their host to choice, show UK research results. Furthermore, the program led to reduced inpatient admission prices, report the experts. The findings revealed lower general expenditure among CHF sufferers who took component in the Better Collectively pilot study compared with their counterparts who did not , with cost savings made in one case. The collaborative team providing care under the pilot initiative included British Center Foundation heart failure professional nurses, Marie Curie Cancers Care nurses, and Marie Curie Tumor Care health care assistants who worked alongside cardiologists, care of the elderly consultants, district nurses, and general practitioners. Continue reading

Circulating free DNA.

CANCER-ID is a recently created European consortium funded by the Innovative Medications Initiative with presently 33 companions from 13 countries with the normal goal of establishing standard protocols for scientific validation of blood-based biomarkers. In this original setting, specialists from all walks of malignancy clinical study, e.g. Clinical and academic research, innovative Small-to-Medium sized Enterprises , diagnostics companies, and the pharmaceutical sector, will work together to establish the medical utility of liquid biopsies in patients with Non-Small Cell Lung Cancer or Her2-therapy resistant breast cancer. Continue reading